8300nok
-4,4 %
Date:2026-07-30Time:10:42:00Latest report:Q4-2025List:Oslo BorsTicker:ONCIN
Market Cap:372 mnokEnterprise Value:194 mnokNet Sales:23,0 mnokEarnings:-155,1 mnokEmployees:0ISIN:NO0013711713

Ratios

10-year key figure history for Oncoinvent turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Oncoinvent with index and moving average MA50 and MA200.

Stockprice:84,60
MA50:57,56
MA200:58,38
Price/MA200:44,9 %
RSI (14):70,9
Price/MA50:47,0 %

Description

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Biotechnology